Categories Earnings, Other Industries

Weight Watchers stock jumps after lifting FY19 earnings outlook

Weight Watchers International (NASDAQ: WW) second quarter 2019 earnings surpassed the Street’s estimates, while revenue missed the predictions. WW stock surged more than 12% in the after-hours as the company lifted its full-year 2019 earnings outlook.

Net income declined 24% to $53.8 million and EPS dropped 23% to $0.78 for the second quarter. On average, analysts had expected Weight Watchers to post earnings of $0.64 per share on revenue of $376.11 million. Revenue slipped 10% year-over-year to $369 million.

Weight Watchers (WW) Q2 2019 earnings. Lifts FY19 earnings outlook

With improving trends, particularly in Digital, WW lifted its earnings guidance for the full year to a range of $1.55 to $1.70 per diluted share from the prior estimated range of $1.35 to $1.55 per share. The company also now expects revenue to be at least $1.4 billion for fiscal 2019.

End of period subscribers in Q2 2019 were up 1.5% versus the prior year period. Digital subscribers were up 8.3% and Studio Subscribers were down 11.1% versus the prior year period.

“Member recruitment trends improved throughout the second quarter as we saw good response to our spring campaigns. End of period subscribers increased 1.5% year-over-year to 4.6 million – our highest level ever for a second quarter,” said CEO Mindy Grossman.

Read: Cost pressure to weigh down on Uber’s Q2 results

He also added, “We are focused on building momentum and look forward to launching our new program innovation later this year, which we believe will accelerate subscriber growth in 2020.”

WW stock, which plummeted to a 52-week low ($16.71) on May 31, ended the day at $21.01, down 1.87%. Weight Watchers stock had plunged 45% since the beginning of 2019 and  77% in the trailing 12 months.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top